# A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

> **NCT00383149** · PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 58 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Ixabepilone
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00383149
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383149, "A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00383149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*